{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010668","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.738044+00:00","generated_at":"2026-06-17T07:02:04.807005+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Biotricity shareholders approve 2023 equity plans, reverse split up to 1:10, and $10M convertible note issuance","bullets":["Approved 2023 Equity Incentive Plan reserving 5M shares plus any unissued from 2016 plan (15.7M votes for).","Authorized reverse stock split within 1:2 to 1:10 ratio, with Board discretion to implement within one year (27.5M for).","Approved potential issuance of up to $10M common stock upon conversion of convertible notes (17.3M for, 629.8K against).","Ratified SRCO Professional Corporation as independent auditor for FY ending March 31, 2023 (28.7M for).","Directors elected: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, Chester White."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010668","json":"https://secwatch.observer/filing/0001493152-23-010668.json","markdown":"https://secwatch.observer/filing/0001493152-23-010668.md","text":"https://secwatch.observer/filing/0001493152-23-010668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:02:04.807005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2cb7084c8f66b6dd65dceba95fbfba3f1ef46e30","claim":"BIOTRICITY INC. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation.","evidence_excerpt":"Year Abstain 5,211,232 189,147 12,566,007 120,883 7. The Company’s stockholders approved and ratified the Company’s 2023 Employee Stock Purchase Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"42795a5e97a5be1bda9d9aacf0ef58cd07a688c2","claim":"BIOTRICITY INC. shareholders approved Approval and ratification of the Company’s 2023 Employee Stock Purchase Plan.","evidence_excerpt":"The Company’s stockholders approved and ratified the Company’s 2023 Employee Stock Purchase Plan","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"749b59db8d463b036aa59bc643cb2e929a1553fa","claim":"BIOTRICITY INC. shareholders approved Approval of potential issuance of securities of up to $10,000,000 of common stock upon conversion of convertible promissory notes.","evidence_excerpt":"The Company’s stockholders approved the potential issuance of securities","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"771d44cdb3a68f50804c5433fe5eedebc6c31daa","claim":"BIOTRICITY INC. shareholders approved Approval to grant discretionary authority to the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-10.","evidence_excerpt":"The Company’s stockholders approved the vote to grant discretionary authority","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"86f5ec7c98a56606d57ab4b9553d85b06f4bc537","claim":"BIOTRICITY INC. shareholders approved Ratification of the appointment of SRCO Professional Corporation as the independent registered public accounting firm for the period ending March 31, 2023.","evidence_excerpt":"The Company’s stockholders ratified the appointment of SRCO Professional Corporation","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"a7c618ed8635aad58c4421a057da790789fb42f5","claim":"BIOTRICITY INC. shareholders approved Advisory non-binding vote to approve the compensation of the named executive officers.","evidence_excerpt":"The Company’s stockholder held an advisory non-binding vote to approve the compensation","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"b9db18ca4cd228a38f6639be9f0c20c0c1bfdaef","claim":"BIOTRICITY INC. shareholders approved Election of six directors.","evidence_excerpt":"Director Nominee Votes For Votes Against Votes Withheld Waqaas Al-Siddiq 17,934,880 10,746,690 152,389 David A. Rosa 16,201,827 10,746,690 1,885,442 Ronald McClurg 18,028,722 10,746,690 58,547 Chester White 17,628,790 10,746,690 458,479","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"bca7788b352e25082f3708b2671aaf5ebfc3596e","claim":"BIOTRICITY INC. shareholders approved Approval and ratification of the Company’s 2023 Equity Incentive Plan, including the reservation of 5,000,000 shares of common stock.","evidence_excerpt":"The Company’s stockholders approved and ratified the Company’s 2023 Equity Incentive Plan","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315223010668/0001493152-23-010668-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}